This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of other endocrine glands and related structures
C3_ENDOCRINE_NAS
endocrine neoplasm: A benign or malignant neoplasm arising from the epithelial cells of an endocrine organ. Representative examples include pituitary gland adenoma, pituitary gland carcinoma, thyroid gland carcinoma, carcinoid tumor, and neuroendocrine carcinoma.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
57 |
4. Check minimum number of eventsNone |
57 |
5. Include endpointsNone |
57 |
6. Filter based on genotype QC (FinnGen only) |
55 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other endocrine glands and related structures
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of other endocrine glands and related structures, including Hilmo
- Malignant neoplasm of endocrine gland
- Solid cancers, helper endpoint
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 55 | 28 | 27 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 53.79 | 49.55 | 58.18 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 57
- Matched controls
- 570
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C75.0
ICD-10 Finland
Malignant neoplasm: Parathyroid gland
+∞
31.1
27
*
8010/3-C75.0
ICD-O-3
Carcinoma, NOS, of parathyroid gland
+∞
24.8
22
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
107.9
20.3
21
*
130
Kela drug reimbursment
Malignant tumour
+∞
19.9
18
*
8680/3-C75.5
ICD-O-3
Paraganglioma, NOS, of aortic body and other paraganglia
+∞
14.1
13
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
20.0
13.9
21
16
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
164.8
13.0
13
*
BAA40
NOMESCO Finland
Unilateral lobectomy of thyroid gland
60.5
12.5
14
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
11.9
11
*
WX408
NOMESCO Finland
General anesthesy, balanced
6.6
11.4
28
73
E83.50
ICD-10 Finland
Hypercalcemia
+∞
10.7
10
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
119.0
9.7
10
*
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
119.0
9.7
10
*
H03AA01
ATC
levothyroxine sodium; systemic
5.3
8.7
26
78
WX404
NOMESCO Finland
Intravenous generell anesthesy
6.1
8.7
19
43
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
104.9
8.7
9
*
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
39.6
8.4
10
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
22.2
8.0
11
6
XX3DW
NOMESCO Finland
Time consuming IT work
16.5
7.8
12
9
BB1BQ
NOMESCO Finland
Extensive scintigraphy of parathyroid gland, 2 isotopes, SPECT and low-dose CT
+∞
7.4
7
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
+∞
7.4
7
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
+∞
7.4
7
*
H02AB02
ATC
dexamethasone; systemic
34.9
7.4
9
*
WX402
NOMESCO Finland
General anaesthesia
5.1
7.2
20
55
H02AB09
ATC
hydrocortisone; systemic
19.8
7.0
10
6
ZXE10
NOMESCO Finland
More than one and less than three hours
4.3
7.0
31
123
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
45.6
6.9
8
*
A03FA01
ATC
metoclopramide; systemic, rectal
6.5
6.4
17
35
WF002
NOMESCO Finland
Radical radiotherapy
+∞
6.4
6
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
6.4
6
*
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
6.4
6
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
6.4
6
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
+∞
6.4
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
51
9.16
15.51
11.8
4.5
0.96
0.98
mmol/l
0.09
27
46
21
35
8.92
13.21
4.2
2.7
—
—
—
0
0
47
201
8.63
11.00
24.6
5.1
1.23
1.22
mmol/l
0.38
31
178
38
186
4.13
6.17
3.4
2.1
—
—
—
0
0
24
86
4.09
6.09
3.2
1.9
—
—
—
0
0
8
5
18.24
5.58
1.1
1.0
—
—
—
0
0
37
188
3.76
5.47
18.2
10.5
1.26
1.23
inr
0.10
16
55
13
23
6.99
5.46
10.8
15.3
95.98
91.96
%
1.14
13
23
18
63
3.71
4.57
1.8
1.3
—
—
—
0
0
12
25
5.78
4.49
14.6
8.1
24.38
25.77
mmol/l
0.74
12
25
11
23
5.66
4.12
11.8
15.1
0.37
0.67
%
2.21
11
23
6
5
13.17
3.85
6.8
1.8
3.12
1.94
u/ml
—
6
5
15
53
3.48
3.69
6.5
2.2
2.31
2.37
g/l
0.13
15
47
7
9
8.66
3.67
1.1
1.0
—
—
—
0
0
16
62
3.20
3.40
6.2
2.0
11.39
15.35
umol/l
1.25
16
55
10
25
4.62
3.27
2.1
1.2
—
—
—
0
0
40
259
2.83
3.21
11.5
4.2
6.38
6.97
mmol/l
1.56
40
236
6
8
8.21
3.13
4.3
1.1
—
—
—
0
0
9
23
4.44
2.92
2.1
1.3
—
—
—
0
0
9
24
4.25
2.81
13.8
14.7
0.79
2.08
%
—
9
24
26
147
2.41
2.62
4.7
2.8
—
—
—
0
0
16
72
2.70
2.57
2.2
1.7
1734.10
1021.72
nmol/l
—
10
53
12
47
2.97
2.46
24.5
8.8
103.75
104.79
mmol/l
0.41
12
47
5
10
5.36
2.11
1.4
1.8
77.40
93.10
%
—
5
10
6
16
4.06
1.99
7.3
4.5
25.25
24.61
mmol/l
—
6
16
5
12
4.45
1.86
1.8
1.2
681.00
321.67
mg/l
—
5
12
21
125
2.08
1.76
2.1
2.0
568.57
193.08
u/l
0.44
21
119
18
101
2.14
1.75
2.9
3.4
0.00
0.00
estimate
-0.00
12
35
10
45
2.48
1.57
2.4
1.1
—
—
—
0
0
5
16
3.32
1.47
1.0
1.2
—
—
—
0
0
6
23
2.79
1.40
1.3
1.3
—
—
—
0
0
5
17
3.12
1.39
1.0
1.2
—
—
—
0
0
5
17
3.12
1.39
1.2
1.8
—
—
—
0
0
5
17
3.12
1.39
1.2
1.7
—
—
—
0
0
9
44
2.24
1.34
2.6
1.1
—
—
—
0
0
43
353
1.89
1.21
4.0
3.7
9.05
9.67
mm/h
0.20
43
321
0
36
0.00
1.19
0.0
2.3
—
—
—
0
0
52
464
2.37
1.16
27.2
10.0
24.85
20.74
mg/l
0.46
47
349
5
21
2.51
1.11
24.4
2.6
0.64
1.71
%
—
5
21
5
101
0.45
1.02
1.6
2.1
—
—
—
0
0
0
29
0.00
1.01
0.0
2.1
—
—
—
0
0
29
232
1.51
0.75
2.9
3.2
0.00
0.00
estimate
-0.00
12
31
28
223
1.50
0.73
2.9
3.2
0.00
0.00
estimate
-0.00
12
39
27
229
1.34
0.44
3.7
4.7
0.00
0.00
estimate
-0.00
12
34
5
33
1.56
0.42
1.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
171.67
—
0
9
19
154
1.35
0.41
3.3
4.1
16.59
10.45
mg/mmol
0.20
11
102
45
421
1.33
0.30
6.8
6.1
39.30
39.81
mmol/mol
0.15
40
389
16
132
1.29
0.30
1.1
1.7
1.55
1.27
mmol/l
0.73
11
109
6
82
0.70
0.26
1.2
1.3
—
11.20
—
0
33
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
2.6
—
—
—
0
0
34
316
1.19
0.20
3.3
3.5
—
—
—
0
0
19
176
1.12
0.09
2.9
3.3
—
—
—
0
0
6
57
1.06
0.09
1.0
1.4
—
—
—
0
0
20
189
1.09
0.05
2.3
1.7
96.17
95.01
pmol/l
0.05
12
95
10
91
1.12
0.04
3.0
3.3
22.40
180.31
ng/l
—
10
67
44
449
0.91
0.04
3.6
4.0
1.42
1.31
mmol/l
0.40
37
405
47
477
0.92
0.02
4.3
4.9
2.65
2.73
mmol/l
0.22
41
437
13
123
1.07
0.02
4.1
3.1
24.32
24.99
%
—
5
51
47
469
1.01
0.00
3.9
4.4
4.59
4.59
mmol/l
0.01
42
430
46
465
0.94
0.00
3.9
4.4
1.39
1.43
mmol/l
0.30
41
422
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
56
0.88
-0.00
11.8
5.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_ENDOCRINE_NAS – Malignant neoplasm of other endocrine glands and related structures
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).